NASDAQ:FENC Fennec Pharmaceuticals (FENC) Stock Price, News & Analysis $6.51 -0.10 (-1.51%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.46▼$6.7050-Day Range$5.81▼$7.3152-Week Range$5.66▼$11.92Volume97,115 shsAverage Volume125,775 shsMarket Capitalization$177.92 millionP/E Ratio217.00Dividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Fennec Pharmaceuticals alerts: Email Address Fennec Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside145.8% Upside$16.00 Price TargetShort InterestBearish8.62% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 4 Articles This WeekInsider TradingSelling Shares$60,555 Sold Last QuarterProj. Earnings Growth41.67%From $0.36 to $0.51 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.69 out of 5 starsMedical Sector483rd out of 936 stocksBiological Products, Except Diagnostic Industry71st out of 154 stocks 3.5 Analyst's Opinion Consensus RatingFennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFennec Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Fennec Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.62% of the float of Fennec Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverFennec Pharmaceuticals has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.Change versus previous monthShort interest in Fennec Pharmaceuticals has recently increased by 8.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFennec Pharmaceuticals does not currently pay a dividend.Dividend GrowthFennec Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FENC. Previous Next 2.9 News and Social Media Coverage News SentimentFennec Pharmaceuticals has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Fennec Pharmaceuticals this week, compared to 1 article on an average week.Search Interest2 people have searched for FENC on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Fennec Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fennec Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,555.00 in company stock.Percentage Held by Insiders10.98% of the stock of Fennec Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fennec Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Fennec Pharmaceuticals are expected to grow by 41.67% in the coming year, from $0.36 to $0.51 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fennec Pharmaceuticals is 217.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 143.26.Price to Earnings Ratio vs. SectorThe P/E ratio of Fennec Pharmaceuticals is 217.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 169.33.Read more about Fennec Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Fennec Pharmaceuticals Stock (NASDAQ:FENC)Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Read More FENC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FENC Stock News HeadlinesJuly 3, 2024 | insidertrades.comFennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Sells $14,902.03 in StockJuly 24 at 5:33 PM | uk.finance.yahoo.comFennec Pharmaceuticals Inc (RV41.MU)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 20, 2024 | americanbankingnews.comContrasting Fennec Pharmaceuticals (NASDAQ:FENC) & Zura Bio (NASDAQ:ZURA)July 1, 2024 | globenewswire.comFennec Pharmaceuticals Announces Management ChangeJuly 1, 2024 | globenewswire.comFennec Pharmaceuticals Announces Management ChangeJune 25, 2024 | globenewswire.comFennec Announces Results of Annual MeetingMay 16, 2024 | finance.yahoo.comFennec Pharmaceuticals Inc. (FENC)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 16, 2024 | markets.businessinsider.comMaintained Buy Rating for Fennec Pharmaceuticals Amidst Revenue Growth and Strategic PartnershipsMay 16, 2024 | markets.businessinsider.comFennec Pharmaceuticals: Temporary Setbacks with Strong Long-Term OutlookMay 14, 2024 | investorplace.comFENC Stock Earnings: Fennec Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | finance.yahoo.comFennec Pharmaceuticals Inc.'s (NASDAQ:FENC) largest shareholders are individual investors who were rewarded as market cap surged US$25m last weekMay 14, 2024 | globenewswire.comFennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | globenewswire.comFennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024April 20, 2024 | investing.comFennec Pharmaceuticals COO sells shares worth over $536kApril 9, 2024 | finance.yahoo.comThose who invested in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago are up 136%April 7, 2024 | uk.investing.comFennec Pharmaceuticals CEO sells shares worth over $950kSee More Headlines Receive FENC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FENC CUSIPN/A CIK1211583 Webwww.fennecpharma.com Phone919-636-4530Fax919-890-0490EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$17.00 Low Stock Price Target$15.00 Potential Upside/Downside+145.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio217.00 Forward P/E Ratio18.08 P/E GrowthN/ANet Income$-16,050,000.00 Net Margins6.33% Pretax Margin6.32% Return on Equity-39.41% Return on Assets8.46% Debt Debt-to-Equity Ratio9.86 Current Ratio6.93 Quick Ratio6.72 Sales & Book Value Annual Sales$21.25 million Price / Sales8.37 Cash FlowN/A Price / Cash FlowN/A Book Value($0.43) per share Price / Book-15.14Miscellaneous Outstanding Shares27,330,000Free Float24,327,000Market Cap$177.92 million OptionableOptionable Beta0.29 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Rostislav Raykov (Age 42)Pres, CEO & Director Mr. Robert C. Andrade (Age 43)Chief Financial Officer Mr. Mark GowlandControllerMr. Lei FangPres of Pharstat IncMs. Anne McKay (Age 64)Regulatory Consultant Key CompetitorsScholar RockNASDAQ:SRRKPrime MedicineNYSE:PRMEGinkgo BioworksNYSE:DNAExscientiaNASDAQ:EXAIREGENXBIONASDAQ:RGNXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 20,602 shares on 7/26/2024Ownership: 0.251%Chris A RallisSold 1,173 sharesTotal: $7,073.19 ($6.03/share)Rosty RaykovSold 2,431 sharesTotal: $14,902.03 ($6.13/share)Rosty RaykovSold 2,431 sharesTotal: $16,433.56 ($6.76/share)Gendell Jeffrey LBought 20,000 shares on 5/15/2024Ownership: 1.107%View All Insider TransactionsView All Institutional Transactions FENC Stock Analysis - Frequently Asked Questions How have FENC shares performed this year? Fennec Pharmaceuticals' stock was trading at $11.22 at the beginning of the year. Since then, FENC stock has decreased by 42.0% and is now trading at $6.51. View the best growth stocks for 2024 here. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc (NASDAQ:FENC) posted its quarterly earnings data on Tuesday, May, 14th. The company reported $0.41 earnings per share for the quarter, missing analysts' consensus estimates of $0.49 by $0.08. The business had revenue of $25.38 million for the quarter, compared to the consensus estimate of $10.46 million. Fennec Pharmaceuticals had a net margin of 6.33% and a negative trailing twelve-month return on equity of 39.41%. Who are Fennec Pharmaceuticals' major shareholders? Fennec Pharmaceuticals' top institutional investors include Bank of New York Mellon Corp (0.25%). Insiders that own company stock include Rosty Raykov, Robert Andrade, Chris A Rallis and Adrian Haigh. View institutional ownership trends. How do I buy shares of Fennec Pharmaceuticals? Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD) and Trevena (TRVN). This page (NASDAQ:FENC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
